Skip to search formSkip to main contentSkip to account menu

0.2 ML ocriplasmin 2.5 MG/ML Injection

Known as: ocriplasmin 0.5 MG in 0.2 ML Injection, OCRIPLASMIN 0.5MG/0.2ML OPH INJ, OCRIPLASMIN 0.5MG/0.2ML INJ,OPH [VA Product] 
National Institutes of Health

Related topics

Related topics

5 relations

Narrower (1)

0.2 ML ocriplasmin 2.5 MG/ML Injection [Jetrea]
InjectionPeptide Hydrolasesocriplasmin

Broader (1)

OPHTHALMICS,OTHER

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Myopic macular hole detachment associated with intravitreal ocriplasmin
2019
2019
Short-term changes in posterior vitreous cortex following intravitreal ocriplasmin for symptomatic vitreomacular traction syndrome: a prospective study
Purpose To describe and analyze short-term posterior vitreous abnormalities following intravitreal ocriplasmin in eyes with… 
Review
2018
Review
2018
INTRAVITREAL OCRIPLASMIN IN CLINICAL PRACTICE: Predictors of Success, Visual Outcomes, and Complications
Purpose: To investigate predictors of success, visual outcomes, and complications of intravitreal ocriplasmin for the treatment… 
Review
2018
Review
2018
Updated Cost-Effectiveness of Intravitreal Ocriplasmin for Vitreomacular Adhesion and Macular Hole.
BACKGROUND AND OBJECTIVE The purpose of this study is to provide an updated assessment of cost-efficacy of intravitreal… 
2018
2018
Multimodal imaging of macular subretinal deposits following intravitreal ocriplasmin injection
2017
2017
Stellenwert von Ocriplasmin bei der Therapie der vitreomakulären Traktion mit und ohne Makulaforamen – erste klinische Erfahrungen
Zusammenfassung Hintergrund Bei der vitreomakulären Traktion (VMT) besteht eine abnormal starke Adhärenz zwischen Netzhaut und… 
2017
2017
LONGITUDINAL MICROPERIMETRY EVALUATION AFTER INTRAVITREAL OCRIPLASMIN INJECTION FOR VITREOMACULAR TRACTION
Purpose: To determine whether improvements in microperimetry testing are associated with anatomic resolution after ocriplasmin… 
2015
2015
Comparison of surgery, intravitreal ocriplasmin and observation in symtomatic vitreomacular traction syndrome
2015
2015
Wild-field Spectral-Domain OCT findings of eyes with symptomatic vitreo-foveal traction treated with intravitreal Ocriplasmin: a look outside the macula.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)